teekid It has been nearly a year since my last Personalis (NASDAQ:PSNL) article, where I provided some background on Personalis and discussed how their NeXT Platform holds immense clinical and commercial potential. At that time, I believed PSNL was undervalued considering the ticker was trading at a negative enterprise value and its long-term growth in a $30B+ market. Over the past 11 months, PSNL went from around $1.61 per share and is now trading over $4.00 per share following encouraging Q2 earnings with ...